Arthritis Biologic Drugs in India: A Prescriber's Guide

This arthritis biologic India guide covers what TNF-inhibitor biologics mechanically do, which Indian-made biosimilars exist and their approximate price gap against the originator, their NPPA/DPCO price-control status, and the cold-chain stocking discipline a hospital pharmacy needs before carrying them.

What are biologic DMARDs, and which ones treat arthritis in India?

Biologic disease-modifying antirheumatic drugs are engineered proteins, not synthesised small-molecule tablets, and the class used most for arthritis in India is the TNF-alpha inhibitor group: etanercept, adalimumab and infliximab. Tumour necrosis factor-alpha is a signalling protein that drives joint inflammation in rheumatoid arthritis, and these three molecules bind and neutralise it through slightly different structures, per CDSCO's own regulatory classification of the class.

Rheumatologists reach for this class after a patient has an inadequate response to methotrexate, the conventional DMARD that itself sits on India's National List of Essential Medicines under the musculoskeletal and disease-modifying agents category. Biologics are not first-line; they follow a documented treatment failure. A patient already escalated to this arthritis biologic India tier has fewer therapeutic options left if a specific product goes out of stock, which is why cost and continuity of supply matter more here than in a first-prescription drug class.

Beyond TNF inhibitors, India's CDSCO-DBT regulatory pathway also covers other biologic classes for autoimmune arthritis, including rituximab and abatacept, though TNF inhibitors remain the most widely prescribed and the most extensively biosimilar-manufactured group domestically.

How do etanercept, adalimumab and infliximab actually differ from each other?

Etanercept is a fusion protein that binds soluble TNF-alpha as a decoy receptor, while adalimumab and infliximab are full monoclonal antibodies that bind TNF-alpha directly with higher affinity and also target its membrane-bound form. That structural difference, documented in CDSCO's 2016 similar-biologics guidance, changes how each drug is administered, how often, and how it behaves when a patient's disease flares.

Infliximab is dosed as an intravenous infusion, which means it is typically given in a hospital or infusion-centre setting rather than self-administered at home. Etanercept and adalimumab are subcutaneous injections, designed for patient or caregiver self-administration after training. That is a meaningful operational difference for any hospital pharmacy deciding what to stock in-house versus what to route through an infusion day-care unit.

None of these molecules is interchangeable unit-for-unit with another in the same class; a rheumatologist switches between them based on response and tolerability, not price alone, which is a separate clinical decision from the biosimilar-versus-originator choice within a single molecule discussed next.

Which biosimilar versions of these biologics are approved and made in India?

India has approved and marketed domestically manufactured biosimilars for all three major TNF inhibitors under the joint CDSCO–Department of Biotechnology "similar biologics" pathway finalised in 2016. Cipla's Etacept, a biosimilar etanercept, was the first such product launched in the country in April 2013, followed by Intas's Intacept in 2015.

Zydus Cadila's Exemptia, a biosimilar adalimumab, was approved in September 2014 and was described at the time as the world's first adalimumab biosimilar to reach any market, ahead of comparable approvals in Europe or the US. Torrent's Adfrar followed as a second adalimumab biosimilar in January 2016, and Epirus Biopharmaceuticals' Infimab brought a domestically developed infliximab biosimilar to market in September 2014.

This depth of domestic biosimilar manufacturing is not incidental. Biocon Biologics, built on manufacturing experience developed serving the Indian market, went on to launch its own adalimumab biosimilar, Hulio, in the United States in July 2023, evidence that an arthritis biologic India first developed for domestic patients can supply regulated markets well beyond its own borders.

How much cheaper is an Indian biosimilar than the originator biologic?

Biosimilar TNF inhibitors manufactured in India have entered the market priced substantially below the originator product, with one clinical trade publication describing Zydus Cadila's adalimumab biosimilar Exemptia as launching at roughly one-fifth the price of AbbVie's originator Humira. Internationally, biosimilars generally enter 20–40% below reference-product pricing, though savings on individual TNF-inhibitor molecules have run considerably higher in specific markets.

That gap is precisely why India's biosimilar sector for arthritis biologics is commercially significant rather than a niche manufacturing exercise. The government's Union Budget 2026–27 proposed a ₹10,000 crore Biopharma SHAKTI scheme specifically to strengthen the country's end-to-end biologics and biosimilar manufacturing ecosystem, aiming for a larger share of the global biopharmaceutical market over the coming years.

For a hospital pharmacy, this price spread is not abstract. A prescriber choosing between an originator TNF inhibitor and a CDSCO-approved biosimilar of the same molecule is choosing between materially different acquisition costs for a drug a patient may need for years, not weeks.

Are TNF-inhibitor biologics covered under NPPA price control?

Not directly, in most cases. NPPA's Drug Price Control Order ceiling pricing applies to formulations scheduled under the National List of Essential Medicines, and NLEM 2022's disease-modifying antirheumatic entry covers methotrexate, the conventional oral DMARD, rather than the TNF-inhibitor biologic class. As of March 2025, NPPA had fixed or re-fixed ceiling prices on 764 formulations under NLEM 2022, a list built primarily around oral and generic essential medicines.

This means etanercept, adalimumab and infliximab — originator or biosimilar — are priced by manufacturers rather than capped by an NPPA ceiling, and prices vary by brand, pack size and manufacturer the way any non-scheduled drug's would. A hospital procurement team cannot assume DPCO protection exists for this drug class the way it might for a scheduled antihypertensive or antibiotic; competitive biosimilar pricing, not price control, is what keeps costs down here.

Why do these biologics require cold-chain storage, and what goes wrong if it fails?

Etanercept, adalimumab and infliximab are protein-based injectables that require storage at 2–8°C throughout transport and shelf life, and none of them may ever be frozen. This is a real operational constraint for any pharmacy stocking them, not a minor label instruction — these are refrigerated products from the manufacturer's warehouse all the way to the point of administration.

Published storage-adherence studies on biologics used for rheumatic disease found troubling gaps in practice: one study found only 11.6% of patient-stored biologics remained within the recommended temperature range, with roughly a third exceeding 8°C for over a week. A separate study found compliance as low as 6.7%. The theoretical consequence of a temperature excursion is protein denaturation and aggregate formation, which can reduce the drug's biological activity or increase its immunogenicity.

A hospital pharmacy's own cold-chain discipline is the one link in this process it fully controls, unlike home storage by the patient. Broken refrigeration, a delayed delivery in Indian summer heat, or a distributor without validated cold-chain transport can compromise a batch before it ever reaches a patient — a risk specific to this drug class that a tablet-based formulary never has to manage.

What should a hospital pharmacy do to stock arthritis biologics safely?

A hospital pharmacy carrying TNF-inhibitor biologics needs validated cold-chain-reliable storage and transport for every unit, not just a refrigerator switched on somewhere in the dispensary, because a single undocumented temperature excursion can render an expensive biologic clinically unreliable without any visible sign of spoilage. This is a materially different operational bar than storing oral DMARDs or NSAIDs.

Continuity of the specific product a patient is stabilised on matters just as much as temperature control. A patient switched mid-therapy from one manufacturer's adalimumab biosimilar to another — or forced to source it from an outside chemist because the hospital pharmacy ran out — faces both a cost shift and a genuine question about product consistency, since biosimilars are not automatically interchangeable the way generic tablets are assumed to be. Reliable in-house stocking of the exact biologic or biosimilar a rheumatologist has prescribed avoids that gap in a chronic autoimmune condition where treatment interruption has real clinical consequences.

Medyzen's guides on managed hospital pharmacy services and pharmacy inventory management for expiry and dead stock cover how a hospital pharmacy builds the cold-chain discipline and stock-continuity practices this drug class demands, without leaving a chronic-disease patient to hunt for their specific biosimilar elsewhere.

Sources

1. 1Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India (2016) – CDSCO & Department of Biotechnology
2. 2'Similar biologics' approved and marketed in India – GaBI Online
3. 3Cipla Launches First Biosimilar of Etanercept in India for Rheumatic Disorders – Pharmaceutical Technology
4. 4Adalimumab Biosimilar Launched for 1/5 Humira Price in India – Rheumatology Live
5. 5After Five Years of Successful Experience Internationally, Biocon Biologics' Hulio Biosimilar to Humira, Now Available in the United States – Biocon
6. 6Transforming India into a Global Biopharma Hub – Budget 2026-27 Series – Press Information Bureau, Government of India
7. 7NPPA has fixed/re-fixed ceiling prices of 928 scheduled formulations under NLEM 2022 – Press Information Bureau, Government of India
8. 8National List of Essential Medicines 2022 – CDSCO / Ministry of Health and Family Welfare
9. 9Problems with Biologic Drug Storage – RheumNow
10. 10Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept – PMC, National Institutes of Health

This article is for informational purposes and is not a substitute for professional medical advice. Consult a treating rheumatologist before starting or switching biologic therapy.